GLP-1 Drugs Reshape U.S. Healthcare Landscape, Prompting Strategic Reset for Providers and Payers
GLP-1 weight-loss drugs are significantly altering the U.S. healthcare system, prompting a strategic reset for providers, insurers, and investors, according to a new Wells Fargo report. These drugs, which have seen a more than 140% increase in use from 2022 to 2024, are shifting the focus from treating obesity-related complications to prevention. This shift is evident in the 34.1% decline in metabolic bariatric surgery volumes during the same period. GLP-1s are also demonstrating the ability to prevent costly complications, such as reducing major adverse cardiovascular events by 20% in high-risk populations. The report indicates that while GLP-1s offer long-term health benefits and potential reductions in healthcare utilization, they present significant near-term drug costs for employers, payers, and Medicare. Employer health costs are projected to rise by 9.5% in 2027, partly due to these drugs. 
